Test Price
2,800 AED✅ Home Collection Available
NSDHL Gene CK Syndrome Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Genetic Counseling by a Consultant Medical Genetics specialist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NSDHL gene NGS test completely sequences the coding region for mutations causing CK syndrome, a rare X-linked neurological disorder characterized by intellectual disability and microcephaly. Early molecular diagnosis enables targeted family counseling, recurrence risk assessment, and tailored management planning. This test utilizes next-generation sequencing to achieve comprehensive coverage of all exons and flanking intronic regions.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity & specificity | ~99% sensitivity |
| Methodology | Next-Generation Sequencing (NGS) | Sanger Sequencing (single‑region focus) |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Cost | 2,800 AED | ~4,000 AED |
Physician Insight & Safety Protocols
“As a Consultant in Medical Genetics, I recognize the profound impact that a confirmed diagnosis of CK syndrome can have on a family. The NSDHL gene test provides definitive molecular evidence, but it must be correlated with clinical findings and inheritance patterns. Pre- and post-test genetic counseling is essential to help families understand recurrence risks, carrier status, and available support resources.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Continuation Advisory
Patients undergoing genetic evaluation for suspected CK syndrome should continue all prescribed therapies unless explicitly directed otherwise by their managing physician. Abrupt discontinuation of anticonvulsants or other neurological medications may precipitate clinical deterioration. Always consult your doctor before making any changes to prescribed treatment.
Exclusion Criteria & Safety Red Flags
- Exclusion: Not recommended for individuals with active bleeding disorders or inability to provide a blood sample. For minors, a legal guardian must provide consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If you experience sudden seizure, loss of consciousness, or severe neurological deterioration, seek emergency medical attention immediately.
- This test is performed under the regulatory framework of the Dubai Healthcare City Authority and complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Patient FAQ & Clinical Guidance
1. What is CK syndrome and why is NSDHL gene testing important?
Snippet: CK syndrome is a rare X-linked intellectual disability disorder caused by mutations in the NSDHL gene, leading to microcephaly and neurological impairments. Testing confirms the molecular diagnosis, enables accurate recurrence risk counseling for families, and guides long-term neurological surveillance.
2. How is the test performed and what is the process?
Snippet: A standard peripheral blood sample is collected via our VIP Mobile Phlebotomy service at your home or at a DHA‑licensed collection centre. DNA is extracted and analysed using advanced NGS technology to detect NSDHL mutations with high precision. Results are typically available within 3 to 4 weeks.
3. What support and guidance are provided after receiving results?
Snippet: Our post-test genetic counseling service provides a telephonic explanation of your NSDHL gene results by a Consultant Medical Genetics specialist. We also offer a written clinical summary for your referring physician and facilitate referral to neurological and genetic support services if needed.
UAE Regulatory & Data Privacy Adherence
This facility operates under DHA Facility License No. 1143. All genetic data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). Results are confidential and shared only with the requesting physician and patient with explicit consent. No third‑party data transfer occurs without prior written authorization.
Clinical & Logistical Metadata
| Test Name | NSDHL Gene CK Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Coding Region & Flanking Intronic Regions |
| ICD-10-CM Code | Q87.89 |
| LOINC Code | 81264-3 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians